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Abstract
To obtain baseline data for cervical cancer prevention in Japan, we analyzed human 
papillomavirus (HPV) data from 5045 Japanese women aged less than 40 years and 
diagnosed with cervical abnormalities at 21 hospitals during 2012-2017. These in-
cluded cervical intraepithelial neoplasia grade 1 (CIN1, n = 573), CIN2-3 (n = 3219), 
adenocarcinoma in situ (AIS, n = 123), and invasive cervical cancer (ICC, n = 1130). 
The Roche Linear Array was used for HPV genotyping. The HPV type-specific rela-
tive contributions (RCs) were estimated by adding multiple infections to single types 
in accordance with proportional weighting attributions. Based on the comparison of 
type-specific RCs between CIN1 and CIN2-3/AIS/ICC (CIN2+), RC ratios were calcu-
lated to estimate type-specific risks for progression to CIN2+. Human papillomavirus 
DNA was detected in 85.5% of CIN1, 95.7% of CIN2-3/AIS, and 91.2% of ICC. Multiple 
infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2-3/AIS, and 
23.7% in ICC (P < .0001). The relative risk for progression to CIN2+ was highest for 
HPV16 (RC ratio 3.78, 95% confidence interval [CI] 3.01-4.98), followed by HPV31 
(2.51, 1.54-5.24), HPV18 (2.43, 1.59-4.32), HPV35 (1.56, 0.43-8.36), HPV33 (1.01, 
0.49-3.31), HPV52 (0.99, 0.76-1.33), and HPV58 (0.97, 0.75-1.32). The relative risk of 
disease progression was 1.87 (95% CI, 1.71-2.05) for HPV16/18/31/33/35/45/52/58, 
but only 0.17 (95% CI, 0.14-0.22) for HPV39/51/56/59/66/68. Human papilloma-
virus 16/18/31/33/45/52/58/6/11 included in a 9-valent vaccine contributed to 
89.7% (95% CI, 88.7-90.7) of CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) of ICC. In 
conclusion, our data support the Japanese guidelines that recommend discriminat-
ing HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9-valent 
vaccine is estimated to provide over 90% protection against ICC in young Japanese 
women.
K E Y W O R D S
adenocarcinoma in situ, cervical intraepithelial neoplasia, human papillomavirus, invasive 
cervical cancer, vaccine
1  | INTRODUC TION
The WHO reported 570 000 new cases of cervical cancer world-
wide in 2018, making it the fourth most common cancer for women 
after breast, colon, and lung cancer.1,2 This disease claims the lives 
of more than 300 000 women annually, mostly in lower income 
countries. Two approaches for cervical cancer prevention, human 
papillomavirus (HPV) vaccines and the use of methods to detect 
carcinogenic HPV infections, have been introduced in the last 2 
decades. Bivalent HPV16/18 and quadrivalent HPV16/18/6/11 
vaccines have the potential to prevent approximately 70% of cer-
vical cancer cases attributable to HPV16 or HPV18 worldwide.3 
Furthermore, the next-generation 9-valent vaccine extends cover-
age to HPV31, 33, 45, 52, and 58,4 which, together, are the second 
most common types associated with cervical cancer globally.5,6 In 
addition to vaccination, effective screening is also needed because 
these vaccines cannot treat preexisting infections or related cervical 
abnormalities.7 Human papillomavirus testing as a primary screening 
tool for cervical cancer has been shown to have greater sensitivity 
and reproducibility for detecting cervical cancer and precancer than 
standard cytological examination.8,9 In the United States, cotesting 
with the HPV test and cytology was recommended for cervical can-
cer screening in 2003,10 and the Netherlands and Australia changed 
their national cervical cancer screening programs from Pap test to 
primary HPV screening in 2017.11,12 Recent models have suggested 
that successful elimination of cervical cancer will be possible by the 
end of this century if 2 major primary prevention strategies, HPV-
based screening and HPV vaccination programs, are scaled up to 
80%–100% coverage over the next 50 years.13
In Japan, cervical cancer rates have risen in recent years be-
cause of a low cancer-screening rate and changes in sexual life-
style.14,15 Cytology-based screening programs are still ongoing, 
with HPV-based screening not yet recommended in the Japanese 
guidelines.16 Although the bivalent and quadrivalent vaccines 
are available, the 9-valent vaccine has not yet been licensed. 
In contrast, Japan is the first country to incorporate full HPV 
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genotyping into cervical intraepithelial neoplasia (CIN) manage-
ment.16 The Japanese clinical guidelines recommend discriminating 
HPV16/18/31/33/35/45/52/58 as more carcinogenic HPV types in 
clinical management of women with histologically proven CIN grade 
1 (CIN1) or CIN2.
Baseline data on HPV genotype attributes in cervical cancer 
and precancer are needed to predict how HPV vaccination, HPV-
based screening, and type-specific CIN management will influence 
cervical cancer prevention. Although global data are available, HPV 
genotype distributions in cervical cancer and precancer vary by 
geographical region and race/ethnicity.3,5 In Japan, limited data are 
available that describe HPV genotype distributions for this disease, 
especially in a reproductive-age population that are mainly targeted 
by HPV vaccination and screening. To address this lack of data, we 
analyzed HPV type-specific data from 5045 Japanese women aged 
less than 40 years and diagnosed with cervical cancer and its pre-
cursors at 21 hospitals during 2012-2017. To our knowledge, this 
is the largest nationwide study of HPV genotype distribution in 
women with cervical abnormalities in Japan. The aim of this study 
was to provide baseline data for cervical cancer prevention in Japan. 
In the present study, we provide a description of the relative risks 
for progression to CIN2 or worse (CIN2+) by individual HPV geno-
types and estimate the potential impact of current and new HPV 
vaccines on cervical cancer and precancer among young Japanese 
women of reproductive age.
2  | MATERIAL S AND METHODS
2.1 | Study design
We prospectively undertook a collaborative hospital-based study 
to monitor the long-term population-level impact of HPV vaccina-
tion in Japan (the MINT Study). Details of the design and methods 
have been provided elsewhere.17,18 In this study, participants con-
sisted of women aged 16-39 years (age at registration) newly diag-
nosed with invasive cervical cancer (ICC), CIN, or adenocarcinoma 
in situ (AIS), without a previous history of treatment for cervical 
diseases, at 21 participating institutions during 2012-2017. All par-
ticipants entered the study only after voluntarily providing signed 
informed consent and were registered together with their vac-
cine history, each year commencing on January 1 and ending on 
December 31. We did not review histological specimens because of 
the relevance to clinical practice. Based on local histological diag-
noses, the study participants were divided into the following three 
groups: (i) Category A, women newly diagnosed with ICC at par-
ticipating facilities each year (registration and HPV genotyping test 
were necessary for all women diagnosed with ICC); (ii) Category B, 
women newly diagnosed with CIN2-3 or AIS (registration was nec-
essary for all women diagnosed with CIN2-3 or AIS, however, HPV 
genotyping tests were carried out until the total number of partici-
pants tested reached 600); and (iii) Category C, women newly diag-
nosed with CIN1 (each year, registration and HPV genotyping were 
carried out until the total number of subjects tested at all facilities 
reached 100).
Institutional ethical and research review boards of the participat-
ing institutions approved the study protocol. This study was regis-
tered in the UMIN Clinical Trials Registry as UMIN000008891.
2.2 | Human papillomavirus detection and 
genotyping procedures
The presence of HPV DNA in cervical samples was determined using 
the Linear Array (LA) assay (Roche Molecular Systems), a commer-
cialized L1 consensus primer-based PCR method that uses a primer 
set designated PGMY09/11. The LA test was carried out according to 
the manufacturer’s recommended protocol. Briefly, exfoliated ecto- 
and endocervical cells were stored in ThinPrep PreservCyt solution 
(Hologic) until DNA extraction. Total cellular DNA was extracted 
using a QIAamp MinElute Media kit (Qiagen). Amplicons were sub-
jected to reverse line blot hybridization for detection of 37 individual 
HPV genotypes (HPV6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51 
to 56, 58, 59, 61, 62, 64, 66 to 73, 81 to 84, and 89). Detection and 
genotyping of HPV were undertaken at a clinical testing laboratory 
(SRL, Tokyo, Japan). All of the HPV DNA assays were carried out by 
individuals who were blinded to the results of the clinical profile for 
each subject.
2.3 | Statistical methods
To add multiple infections to HPV type-specific analyses, we cal-
culated relative contributions (RCs) of each HPV type among HPV-
positive women by category.5,6 Multiple infections were added to 
single types in accordance with a proportional weighting attribution. 
For example, if an ICC lesion is positive for both HPV16 and HPV52 
(multiple infection) and there are 8 cases infected by HPV16 alone 
(single infection) and 2 cases infected by HPV52 alone (single infec-
tion) in an ICC category, then 0.8 [8/(8 + 2)] of the multitype infected 
ICC lesion was attributed to HPV16 and 0.2 [2/(8 + 2)] attributed to 
HPV52 in Category A.
To estimate HPV genotype-specific risks for progression from 
CIN1 to CIN2 or worse, RC ratios and 95% confidence intervals (CIs) 
were calculated using JMP 10.0J software (SAS Institute). The HPV 
types detected only among a small number of women (fewer than 
50) were excluded from this analysis. In addition, to estimate the im-
pact of current HPV vaccines among young Japanese women, com-
bined RCs of HPV16/18 (carcinogenic types included in bivalent and 
quadrivalent vaccines) and HPV16/18/31/33/45/52/58 (carcinogenic 
types included in a 9-valent vaccine) were calculated according to 
disease severity, histology, and age group (20-24, 25-29, 30-34, and 
35-39 years), using HPV type-specific data from unvaccinated cases. 
The χ2 test for trend was used to analyze the prevalence of multiple 
infections according to disease severity. Two-sided P values were ob-
tained in all tests and considered significant when P was less than .05.
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All CIN2-3 AIS All SCC Non-SCC
(N = 573) (N = 3342) (N = 3219) (N = 123) (N = 1130) (N = 720) (N = 410)
n % n % n % n % n % n % n %
HPV positive 490 85.5 3195 95.6 3081 95.7 114 92.7 1030 91.2 672 93.3 358 87.3
Single infection 327 57.1 1993 59.6 1903 59.1 90 73.2 862 76.3 544 75.6 318 77.6
6 6 1.0 4 0.1 4 0.1 0 0.0 2 0.2 2 0.3 0 0.0
11 2 0.3 2 0.1 2 0.1 0 0.0 0 0.0 0 0.0 0 0.0
16 27 4.7 723 21.6 695 21.6 28 22.8 475 42.0 368 51.1 107 26.1
18 9 1.6 104 3.1 57 1.8 47 38.2 173 15.3 46 6.4 127 31.0
26 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
31 9 1.6 149 4.5 149 4.6 0 0.0 19 1.7 18 2.5 1 0.2
33 5 0.9 46 1.4 46 1.4 0 0.0 4 0.4 4 0.6 0 0.0
35 1 0.2 13 0.4 13 0.4 0 0.0 1 0.1 1 0.1 0 0.0
39 9 1.6 14 0.4 14 0.4 0 0.0 7 0.6 4 0.6 3 0.7
40 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
42 4 0.7 0 0.0 0 0.0 0 0.0 2 0.2 0 0.0 2 0.5
43 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
44 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
45 3 0.5 8 0.2 7 0.2 1 0.8 6 0.5 2 0.3 4 1.0
51 21 3.7 52 1.6 52 1.6 0 0.0 5 0.4 3 0.4 2 0.5
52 29 5.1 318 9.5 316 9.8 2 1.6 10 0.9 8 1.1 2 0.5
53 9 1.6 5 0.1 5 0.2 0 0.0 1 0.1 0 0.0 1 0.2
54 2 0.3 2 0.1 2 0.1 0 0.0 1 0.1 0 0.0 1 0.2
55 1 0.2 1 0.0 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0
56 21 3.7 13 0.4 13 0.4 0 0.0 4 0.4 4 0.6 0 0.0
58 34 5.9 301 9.0 300 9.3 1 0.8 25 2.2 22 3.1 3 0.7
59 5 0.9 6 0.2 6 0.2 0 0.0 11 1.0 8 1.1 3 0.7
61 2 0.3 0 0.0 0 0.0 0 0.0 1 0.1 1 0.1 0 0.0
62 4 0.7 4 0.1 4 0.1 0 0.0 4 0.4 2 0.3 2 0.5
64 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
66 13 2.3 10 0.3 10 0.3 0 0.0 2 0.2 1 0.1 1 0.2
67 2 0.3 4 0.1 4 0.1 0 0.0 1 0.1 0 0.0 1 0.2
68 8 1.4 6 0.2 6 0.2 0 0.0 1 0.1 1 0.1 0 0.0
69 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
70 2 0.3 2 0.1 2 0.1 0 0.0 2 0.2 0 0.0 2 0.5
71 2 0.3 3 0.1 3 0.1 0 0.0 3 0.3 1 0.1 2 0.5
72 1 0.2 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
73 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
81 1 0.2 1 0.0 1 0.0 0 0.0 1 0.1 0 0.0 1 0.2
82 7 1.2 45 1.3 45 1.4 0 0.0 0 0.0 0 0.0 0 0.0
83 0 0.0 1 0.0 1 0.0 0 0.0 0 0.0 0 0.0 0 0.0
84 3 0.5 2 0.1 1 0.0 1 0.8 0 0.0 0 0.0 0 0.0
89 1 0.2 2 0.1 1 0.0 1 0.8 1 0.1 0 0.0 1 0.2
Undetermined 0 0.0 5 0.1 5 0.2 0 0.0 0 0.0 0 0.0 0 0.0
(Continues)
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3  | RESULTS
3.1 | Detection and genotyping of HPV
A total of 7709 women aged less than 40 years, who were newly 
diagnosed with CIN1 (n = 589), CIN2-3/AIS (n = 5828), or ICC 
(n = 1292) at 21 participating institutions, were registered between 
2012 and 2017. In the present study, HPV-genotyping assays were 
undertaken for CIN1 and CIN2-3/AIS until the total number of sam-
ples tested reached 100 and 600 each year, respectively. Although 
all ICC cases were to be tested for HPV genotype, HPV typing re-
sults were lacking among 162 early-stage ICC cases, because of an 
ICC diagnosis after conization. Thus, we obtained HPV type-specific 
data from 5045 women (CIN1, n = 573; CIN2-3/AIS, n = 3342; ICC, 
n = 1130). The mean age ± SD of these women was 32.4 ± 4.6 years 
at the registration date: 30.6 ± 5.3 years in CIN1, 32.2 ± 4.6 years in 
CIN2-3/AIS, and 34.0 ± 3.8 years in ICC.
Human papillomavirus type-specific data from 5045 women 
are shown in Table 1. Human papillomavirus DNA was detected in 
93.5% (4715/5045) of the study subjects: 85.5% in CIN1, 95.7% in 
CIN2-3/AIS, and 91.2% in ICC. Although 38 cases with mixed AIS/
CIN2-3 lesions were classified into AIS, HPV type-specific data were 
similar between pure AIS and mixed AIS/CIN2-3 (data not shown). 
Among single infections, a total of 31 HPV types were detected in 
CIN1, 28 types in CIN2-3/AIS, and 25 types in ICC. Infections from 
multiple types were found in 36.9% (1863/5045) of the study sub-
jects. Multiple infections decreased with disease severity: 42.9% in 
CIN1, 40.4% in CIN2-3/AIS, and 23.7% in ICC (P < .0001).
3.2 | Human papillomavirus type-specific risk for 
cervical cancer and precancer
Using data from HPV-positive women, including multiple infections, 
HPV type-specific RCs among young Japanese women diagnosed 
with CIN1, CIN2-3/AIS, or ICC between 2012 and 2017 were cal-
culated (Table 2). For ICC, the most common HPV types were, in 
order of decreasing RC, HPV16 (62.3%), HPV18 (22.7%), HPV58 
(3.2%), HPV31 (2.9%), HPV52 (1.6%), HPV59 (1.3%), and HPV39 
(0.9%) (Figure 1A). For CIN2-3/AIS, HPV16 was also most prevalent 
(40.0%), followed by HPV52 (17.2%), HPV58 (16.3%), HPV31 (8.3%), 
HPV18 (4.9%), HPV51 (3.2%), and HPV82 (2.4%) (Figure 1B). The 5 
most common HPV types were HPV16, HPV18, HPV31, HPV52, and 
HPV58 in ICC as well as in CIN2-3/AIS. These 5 types contributed 
to 86.7% of CIN2-3/AIS and 92.7% of ICC. A remarkable contribu-
tion of HPV18 was observed in AIS (51.6%; 95% CI, 42.1-59.9) and 
nonsquamous cell carcinomas (non-SCC) (47.8%; 95% CI, 42.8-52.9). 
In CIN1, HPV52 (13.6%) was the most common genotype, followed 
by HPV58 (13.5%), HPV16 (12.0%), HPV56 (8.6%), HPV51 (8.1%), 
HPV66 (5.6%), and HPV53 (4.4%).
Based on the comparison of type-specific RCs between CIN1 
and CIN2-3/AIS/ICC, the estimated risks for progression to CIN2+ 
was highest in HPV16 (RC ratio 3.78; 95% CI, 3.01-4.98), followed by 
HPV31 (2.51; 95% CI, 1.54-5.24), HPV18 (2.43; 95% CI, 1.59-4.32), 
HPV35 (1.56; 95% CI, 0.43-8.36), HPV33 (1.01; 95% CI, 0.49-3.31), 
HPV52 (0.99; 95% CI, 0.76-1.33), HPV58 (0.97; 95% CI, 0.75-1.32), 
HPV82 (0.74; 95% CI, 0.39-1.76), and HPV45 (0.43; 95% CI, 0.13-
2.91) (Figure 2). The estimated risk of disease progression was statis-
tically significant for HPV16, HPV18, and HPV31 (P < .05).
The combined RCs of HPV16/18/31/33/35/45/52/58, carcino-
genic types regarded as higher-risk types in the Japanese clinical 
guidelines, increased according to disease severity (CIN1, 48.7%; 
CIN2-3/AIS, 89.9%; ICC, 93.8%). Conversely, the combined RCs 
of the other carcinogenic types, HPV39/51/56/59/66/68, de-
creased with disease severity (CIN1, 30.8%; CIN2-3/AIS, 5.9%; 
ICC, 3.6%). A similar trend was observed for nononcogenic types 
(CIN1, 20.5%; CIN2-3/AIS, 4.2%; ICC, 2.6%). Accordingly, the rela-
tive risk for progression to CIN2+ was 1.87 (95% CI, 1.71-2.05) for 
HPV16/18/31/33/35/45/52/58, but only 0.17 (95% CI, 0.14-0.22) 
for HPV39/51/56/59/66/68 and 0.19 (95% CI, 0.14-0.25) for non-
carcinogenic types.
3.3 | Estimating the impact of HPV vaccines on 
cervical cancer and precancer in Japan
Clinical studies of HPV vaccines have reported close to 100% protec-
tion against vaccine type-related infections and diseases. Therefore, 
the combined RCs of HPV types included in current HPV vaccines 
were specifically analyzed to estimate the potential impact of biva-
lent, quadrivalent and 9-valent vaccines. Of 5045 study participants 




All CIN2-3 AIS All SCC Non-SCC
(N = 573) (N = 3342) (N = 3219) (N = 123) (N = 1130) (N = 720) (N = 410)
n % n % n % n % n % n % n %
Multiple 
infections
246 42.9 1349 40.4 1316 40.9 33 26.8 268 23.7 176 24.4 92 22.4
HPV negative 83 14.5 147 4.4 138 4.3 9 7.3 100 8.8 48 6.7 52 12.7
Abbreviations: AIS, adenocarcinoma in situ; CIN, cervical intraepithelial neoplasia; SCC, squamous cell carcinoma.
TA B L E  1   (Continued)
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vaccination. Prevalence of HPV16/18 was significantly reduced 
among vaccinated women compared with unvaccinated women 
(33.0% [35/106] vs 47.7% [1535/3213], P = .003). Thus, vaccinated 
women (n = 157) were excluded from this analysis.
The combined RCs of HPV16/18/31/33/45/52/58/6/11, all 9 
types included in the 9-valent vaccine, were 89.7% (95% CI, 88.7-
90.7) in CIN2-3/AIS and 93.8% (95% CI, 92.4-95.3) in ICC, with 
HPV31/33/45/52/58 contributing to 44.3% (95% CI, 42.7-45.9) and 
F I G U R E  1   Cumulative proportion 
of cervical cancer and precancer cases 
attributed to the most frequent human 
papillomavirus (HPV) types in Japan. 
Cumulative relative contributions (RCs) 
of the 10 most frequent HPV types in 
invasive cervical cancer (A) and precancer 
(B) are shown
F I G U R E  2   Estimates of human 
papillomavirus (HPV) type-specific 
relative risks for progression to cervical 
intraepithelial lesion grade 2 (CIN2) 
or worse. To estimate type-specific 
relative risks for progression to CIN2-3, 
adenocarcinoma in situ (AIS) or invasive 
cervical cancer (ICC), relative contribution 
(RC) ratios (CIN2-3/AIS/ICC vs CIN1) were 
calculated for each HPV type. Red bars 
represent oncogenic HPV types; green 
bars indicate nononcogenic HPV types. 
CI, confidence interval
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8.7% (95% CI, 7.1-10.4), respectively. Thus, the inclusion of the ad-
ditional 5 types provides more protection against CIN2-3/AIS than 
ICC. Human papillomavirus 6/11 rarely contributed to cervical can-
cer or precancer (additional RCs of HPV6/11 were very small [less 
than 0.3%]). Hereafter, only the RCs of carcinogenic HPV types in-
cluded in HPV vaccines were evaluated to estimate the possible im-
pact of current HPV vaccines.
The combined RCs of HPV16/18/31/33/45/52/58 were 93.6% 
(95% CI, 92.1-95.1) for ICC, with 8.7% (95% CI, 7.1-10.4) of ICC 
cases positive for HPV31/33/45/52/58 (Figure 2). The RCs of 
HPV16/18/31/33/45/52/58 were similar between SCC and Non-
SCC (94.1% [95% CI, 92.3-95.9] vs 92.6% [95% CI, 89.9-95.4]). The 
RCs of HPV31/33/45/52/58 newly added to the 9-valent HPV vac-
cine were greater in SCC than in non-SCC (11.4% [95% CI, 9.0-13.8] 
vs 3.7% [95% CI, 1.9-5.6]).
The combined RCs of HPV16/18/31/33/45/52/58 were 89.5% 
(95% CI, 88.5-90.5]) in CIN2-3/AIS, with HPV31/33/45/52/58 con-
tributing to 44.3% (95% CI, 42.7-45.9) (Figure 3). Although the RCs 
of HPV31/33/45/52/58 were, by far, greater in CIN2-3 than in AIS 
(45.5% [95% CI, 43.9-47.2] vs 11.6% [95% CI, 6.3-16.8]), the RCs 
of HPV16/18/31/33/45/52/58 were higher in AIS than in CIN2-3 
(97.4% [95% CI, 94.8-100] vs 89.2% [95% CI, 88.1-90.2]) due to a 
greater contribution of HPV16/18 in AIS.
The RCs of HPV16/18/31/33/45/52/58 in ICC were similar be-
tween age groups (94.0% for 20-24 years, 95.5% for 25-29 years, 
94.2% for 30-34 years, and 92.8% for 35-39 years) (Figure 4A). As 
previously reported, the RCs of HPV16/18 were greater in younger 
age groups. By contrast, the RCs of HPV31/33/45/52/58 altogether 
increased with age, to compensate for the decrease of HPV16/18 in 
RCs. A similar finding was observed for CIN2-3/AIS (Figure 4B).
These observations suggest that the 9-valent vaccine would 
provide approximately 90% protection against cervical cancer and 
precancer in Japan, regardless of histology (squamous cell histology 
vsglandular cell histology) or age.
4  | DISCUSSION
The present study provided representative data for HPV type con-
tributions to cervical cancer and precancer in Japan. We focused on 
young Japanese women of reproductive age, because these women 
are the major target population of cervical cancer screening and vac-
cination. In addition, the large dataset enabled us to evaluate the 
oncogenic potential of individual HPV genotypes and to estimate the 
population-based impact of bivalent, quadrivalent, or 9-valent HPV 
vaccines.
Based on a comparison of type-specific RCs between CIN1 and 
CIN2-3/AIS/ICC, our data indicated that the relative risks of progres-
sion to CIN2+ vary considerably by HPV genotype. The relative risk 
was highest in HPV16, followed by HPV31, HPV18, HPV35, HPV33, 
HPV52, HPV58, HPV82, and HPV45 (Figure 2). The relatively high 
progression risk for HPV31 was consistent with that of our previ-
ous study.19 We also confirmed that the 8 carcinogenic types of 
HPV16/18/31/33/35/45/52/58 confer far higher risks for progres-
sion to CIN2+ compared with the other carcinogenic and noncar-
cinogenic types. This supports the Japanese clinical guidelines that 
recommend discriminating these 8 types from other carcinogenic 
types in CIN management to assist in making a treatment decision 
for women with CIN2 or determine follow-up intervals according to 
risk stratification of progression to CIN3+.16
Of the 8 higher-risk types mentioned above, the most important 
HPV types are HPV16, 18, 31, 52, and 58 because they were the 5 
most common types in both CIN2-3/AIS and ICC. Both HPV52 and 
HPV58 were lower in the estimated risk of progression (Figure 2), 
but much higher in the proportional contribution to cervical cancer 
and precancer (Figure 1), compared with HPV33 and HPV35. The 
5 HPV types (HPV16, 18, 31, 52, and 58) contributed to 86.7% of 
CIN2-3/AIS and 92.7% of ICC, while incorporating 9 more carcino-
genic types adds only an additional 5.1% and 3.7%, respectively. 
Human papillomavirus 16, 18, 31, 52, and 58 were also the top 5 
genotypes contributing to cervical cancer in recent HPV studies in 
Japan.19-21
Current HPV tests for cervical cancer screening include as 
many as 13-14 carcinogenic types, which lead to a high sensitivity 
for detecting CIN2+, but substantial loss in specificity.8 Therefore, 
HPV tests require additional triage to stratify screen-positive 
women according to risks for CIN2+ or CIN3+.22 Of the 14 car-
cinogenic types, progression risk and disease contribution varied 
considerably by individual HPV genotype.3,5,19-21,23 Thus, HPV 
genotyping could serve as triage to characterize an HPV-positive 
woman’s risk more accurately. Currently, HPV tests discriminating 
HPV16 and 18 (Cobas; Roche Molecular Systems) and HPV16, 18, 
31, 45, 51, and 52 (Oncoclarity; Becton Dickinson) are available. In 
F I G U R E  3   Cumulative relative contribution of the oncogenic 
types included in a 9-valent human papillomavirus (HPV) vaccine 
in cervical cancer and precancer that are positive for HPV DNA, 
by histology. Invasive cancer includes squamous cell carcinoma 
(SCC) and others (Non-SCC). Cervical precancer includes cervical 
intraepithelial neoplasia grade 2-3 (CIN2-3) and adenocarcinoma 
in situ (AIS). A 9-valent HPV vaccine covers HPV16 (red), HPV18 
(green), and HPV31/33/45/52/58 (blue). Other HPV types are 
indicated in gray
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Japan, however, HPV16, 18, 31, 52, and 58 should be considered 
when a new HPV test is developed for stratifying Japanese women 
according to risks for CIN2+ or CIN3+, although further studies 
are needed.
Human papillomavirus 82 was unexpectedly estimated to repre-
sent a higher risk type compared with HPV45. Although HPV82 con-
tributed to 2.3% of CIN2-3/AIS, there was no ICC case positive for 
HPV82. Recent HPV studies in Japan also reported no association 
between HPV82 and ICC.20,21 Global metaanalyses have suggested 
that HPV82 could be carcinogenic, accounting for less than 0.1% of 
ICC globally.5
The combined contribution of all carcinogenic types (HPV16, 18, 
31, 33, 45, 52, and 58) in the 9-valent vaccine was 89.4% for CIN2-3/
AIS and 93.6% for ICC among unvaccinated women, suggesting that 
the 9-valent vaccine would provide approximately 90% protection 
against cervical cancer and precancer in young Japanese women. 
The estimated impact of the 9-valent vaccine was approximately 
10% higher than global estimates from metaanalyses of worldwide 
HPV distribution studies.5,6 This could be explained by a relatively 
younger age in our study subjects and/or a higher contribution of 
HPV52 and HPV58 in Japan. The addition of HPV31, 33, 45, 52, 
and 58 to the prophylactic HPV vaccine would increase protec-
tion against ICC by only 8.8%, but against CIN2-3/AIS by 44.3%. 
Furthermore, the addition of these 5 types would increase protec-
tion against AIS by only 11.5%, but against CIN2-3 by 45.6%. These 
observations suggest that a shift from bivalent or quadrivalent vac-
cines to a 9-valent vaccine could provide greater protection against 
CIN2-3 compared with ICC and AIS in Japan. Also, the combined RCs 
of all carcinogenic HPV types in the 9-valent vaccine were 48.7% for 
CIN1. Given that most screen-positive women are diagnosed with 
CIN1, the number of colposcopy referrals could be reduced to half in 
the era of the 9-valent vaccine.
Human papillomavirustype distributions in ICC also vary greatly by 
age.19,24,25 For instance, HPV16/18 prevalence in ICC in the present 
study was much higher than previously reported across a wide age 
range (85.0% vs 65.4-71.2%).20,21 This is explained by a younger age 
of our study subjects, in keeping with previous reports.19,24,25 In our 
previous study, HPV16/18 prevalence in ICC was highest in women 
aged 20-29 years (90.0%), followed by a gradual decline, and lowest 
in women aged 60 years or older (56.3%).19 In the present study, even 
among women aged 20-39 years, HPV16/18 prevalence in ICC peaked 
in women aged 20-24 years (92.9%), decreased with age thereafter, 
and was found to be lowest in women aged 35-39 years (82.5%). 
Therefore, the current HPV16/18 vaccines have been estimated to 
provide greater protection against ICC among younger women.19 
However, the estimated protection of the 9-valent vaccine did not 
differ by age, because the additional RCs of HPV31/33/45/52/58 in-
creased with age (Figure 4B). A similar trend for HPV type contribution 
was observed for CIN2-3/AIS (Figure 4A). Accordingly, the 9-valent 
vaccine would provide approximately 90% protection against both 
cervical cancer and precancer, regardless of a woman’s age.
The existence of multiple infections complicates the estimates 
of type-specific contributions in such cases. In cases with multiple 
infections, a conservative hierarchical approach attributes each le-
sion to the most oncogenic HPV type among all HPV types detected. 
However, this method tends to overestimate the contribution of 
HPV16 and HPV18 that are considered to have the greatest onco-
genic potential. In the present study, we used another method, in 
which multiple infections were added to single types in accordance 
with a proportional weighting attribution in women with single in-
fections. Although this method might overestimate the contribution 
of less oncogenic types, recent studies of HPV type distributions 
have used this method.3,5,26
The present study has several potential limitations. First, the 
histology of our cervical specimens was not reviewed by central 
pathologists. Therefore, misclassification of histology might have 
affected our results. However, the good agreement with previous 
reports in Japan suggests the correctness and representativeness 
F I G U R E  4   Cumulative relative 
contribution of the oncogenic 
types included in a 9-valent human 
papillomavirus (HPV) vaccine in cervical 
cancer and precancer that are positive 
for HPV DNA, by age group. A 9-valent 
HPV vaccine covers HPV16 (red), HPV18 
(green), and HPV31/33/45/52/58 (blue). 
Other HPV types are indicated in gray. 
Relative contributions (RCs) of these types 
in cervical cancer (A) and precancer (B) 
are shown for 4 age groups (20-24, 25-29, 
30-34 and 35-39 years)
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of our data to a considerable extent.19-21 Our findings depended 
on local diagnoses by participating institutions that could reflect 
clinical practice in Japan. Second, the Roche LA assay cannot di-
rectly detect HPV52. Specimens that tested negative for HPV33, 
35, and 58 individually, but were positive for the HPVmix (a com-
bined probe for HPV33, 35, 52, and 58), were considered to be 
HPV52 positive. Thus, LA cannot discriminate HPV52 infection 
when it is coinfected with HPV33, 35, and 58, suggesting that 
HPV52 prevalence might be underestimated in the present study. 
Finally, we identified 8.8% (100/1130) of HPV-negative ICC cases, 
particularly among women with adenocarcinoma (12.7% [52/410]). 
Unfortunately, we cannot assess the quality of these HPV-negative 
specimens because DNA samples were not collected from the com-
mercial laboratory. However, this proportion of HPV-negative ICC 
was similar to that of recent reports using fresh cervical samples 
in Japan.19-21 As previously suggested,5,27,28 HPV negativity in ICC 
was most likely to be attributable to technical artifacts, although 
we cannot completely ignore the possibility that a small fraction of 
ICC cases might arise independently of HPV exposure. In the pres-
ent study, data from HPV-positive cases were analyzed in detail.
In conclusion, we updated HPV type-specific risks of and contribu-
tions to cervical cancer and precancer in Japan, using a large dataset 
from young Japanese women with cervical abnormalities. Our find-
ings support the Japanese guidelines that recommend discriminating 
HPV16, 18, 31, 33, 35, 45, 52, and 58 in the clinical management of 
women with CIN1 or CIN2.16 Our data and previous reports suggest 
that type-specific HPV-based screening tests and protocols should 
focus on HPV16, 18, 31, 52, and 58.19-21 We also evaluated the likely 
impact of current and 9-valent vaccines on cervical cancer and precan-
cer. The 9-valent vaccine would reduce most HPV-related cervical can-
cer and precancer among Japanese women up to an age of 40 years, 
with a greater reduction of HPV31, 33, 45, 52, and 58 for CIN2-3.
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